ADCendo ApS
๐ฉ๐ฐDenmark
- Country
- ๐ฉ๐ฐDenmark
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.adcendo.dk
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
Phase 1
Recruiting
- Conditions
- Metastatic Soft Tissue SarcomaUnresectable Soft Tissue Sarcoma
- Interventions
- Biological: Antibody-drug conjugate (ADC)
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Adcendo ApS
- Target Recruit Count
- 270
- Registration Number
- NCT06797999
- Locations
- ๐บ๐ธ
University of Colorado Denver, Aurora, Colorado, United States
๐บ๐ธUniversity of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York City, New York, United States
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Adcendo ApS
- Target Recruit Count
- 66
- Registration Number
- NCT06597721
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
๐ฆ๐บScientia Clinical Research, Randwick, New South Wales, Australia
๐ฆ๐บSouthern Oncology Clinical Research Unit, Bedford Park, South Australia, Australia
ยฉ Copyright 2025. All Rights Reserved by MedPath